Novartis’ Ianalumab Shows Promise for Sjögren’s Syndrome and Blood Disorder in New Studies

Novartis has announced encouraging results from two pivotal studies involving its experimental drug, ianalumab, targeting two different autoimmune indications. As reported by BioPharma Dive, the Swiss pharmaceutical company revealed positive data…

Continue Reading Novartis’ Ianalumab Shows Promise for Sjögren’s Syndrome and Blood Disorder in New Studies

AbbVie’s IL-1 Drug Falters in Phase 2 Ulcerative Colitis Trial: What Happened and What’s Next?

AbbVie, a global biopharmaceutical leader, has reported disappointing results from a phase 2 clinical trial evaluating its interleukin-1 (IL-1) targeting drug, ABBV-668, as a monotherapy for patients with moderate to…

Continue Reading AbbVie’s IL-1 Drug Falters in Phase 2 Ulcerative Colitis Trial: What Happened and What’s Next?

Acknowledgement: Patient Worthy is honored to be a media partner of the National Organization for Rare Disorders (NORD).  The mission of NORD is to improve the health and well-being of…

Continue Reading

Eosinophilic Gastrointestinal Diseases Linked to Higher Rates Among Patients with Allergies

Recent research highlights a significant connection between eosinophilic gastrointestinal diseases (EGIDs) and atopic conditions such as asthma, eczema, and allergic rhinitis. EGIDs, which include disorders like eosinophilic esophagitis, gastritis, and…

Continue Reading Eosinophilic Gastrointestinal Diseases Linked to Higher Rates Among Patients with Allergies

Illuminating Protein Dynamics: Novel Insights from High-Speed Atomic Force Microscopy

A recent research article in ScienceDirect.com details a breakthrough in visualizing the rapid, complex movements of proteins using high-speed atomic force microscopy (HS-AFM). This cutting-edge imaging technology allows scientists to…

Continue Reading Illuminating Protein Dynamics: Novel Insights from High-Speed Atomic Force Microscopy